Patents by Inventor Xiaoyu Zhang

Xiaoyu Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Key processing method and device
    Patent number: 10721056
    Abstract: An attack on an RSA encryption algorithm based on simple power analysis (SPA) is thwarted by scrambling the sliding window sequence that results from performing sliding window processing on a power exponent. The sliding window sequence is scrambled with a random code that is utilized to determine an adjustment tendency and an adjustment length.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: July 21, 2020
    Assignee: Alibaba Group Holding Limited
    Inventor: Xiaoyu Zhang
  • CRYSTALLINE FORMS OF GSK1278863, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
    Publication number: 20200216399
    Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Inventors: Minhua Chen, Yanfeng Zhang, Jinqiu Wang, Xiaoyu Zhang
  • CRYSTAL FORMS OF OZANIMOD AND PREPARATION METHOD THEREFOR
    Publication number: 20200216404
    Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
    Type: Application
    Filed: August 18, 2017
    Publication date: July 9, 2020
    Applicant: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
    Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaoting ZHAI, Kaiqiang YAN, Chaohui YANG, Xiaoyu ZHANG
  • Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
    Patent number: 10703724
    Abstract: The present disclosure relates to novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation and uses thereof. Crystalline form CS1, form CS2 and form CS8 of the present disclosure can be used for preparing drugs treating anemia, which providing new choices for preparing drugs of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid, and having very important value for drug development.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 7, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Po Zou, Jinqiu Wang, Xiaoyu Zhang
  • COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION
    Publication number: 20200190105
    Abstract: Disclosed herein are methods and compounds for inducing DDB1- and CUL4-associated factor 16 (DCAF16)-mediated protein degradation in mammalian cells. In some embodiments, also disclosed herein are methods of modulating the substrate selectivity of a DCAF16-CUL4-RBX1-DDB1 complex (CRL4) for modulating protein degradation.
    Type: Application
    Filed: October 11, 2019
    Publication date: June 18, 2020
    Inventors: Benjamin CRAVATT, Vincent CROWLEY, Xiaoyu ZHANG
  • CRYSTALLINE FORM OF OREXIN RECEPTOR ANTAGONIST, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF
    Publication number: 20200190060
    Abstract: The present disclosure provides a novel crystalline form of Lemborexant and processes for preparation thereof. Pharmaceutical composition containing Lemborexant, and use of Lemborexant for preparing orexin receptor antagonist drug, and use of Lemborexant for preparing drugs treating insomnia and irregular sleep-wake rhythm disorder are also provided. The crystalline form of the present disclosure have one or more improved properties compared with crystalline forms of prior arts, and has significant values for future drug optimization and development.
    Type: Application
    Filed: January 30, 2020
    Publication date: June 18, 2020
    Inventors: Minhua Chen, Yanfeng Zhang, Chunxiang Huang, Xiaoyu Zhang
  • CRYSTALLINE FORMS OF OZANIMOD AND OZANIMOD HYDROCHLORIDE, AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20200157065
    Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 21, 2020
    Inventors: Minhua Chen, Xiaoyu Zhang, Yanfeng Zhang, Chaohui Yang, Xiaoting Zhai, Kaiqiang Yan
  • SYSTEM AND METHOD FOR MONITORING CARDIOMYOCYTE BEATING, VIABILITY, MORPHOLOGY AND ELECTROPHYSIOLOGICAL PROPERTIES
    Publication number: 20200158670
    Abstract: Devices, systems and methods for monitoring excitable cells, such as cardiomyocytes, on microelectrode arrays that couple the electro-stimulation of excitable cells to induce or regulate cardiomyocyte beating and the simultaneous measurement of impedance and extracellular recording to assess changes in cardiomyocyte beating, viability, morphology or electrophysical properties in response to a plurality of treatments.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 21, 2020
    Inventors: Xiaobo Wang, Wei Ouyang, Nan Li, Tianxing Wang, Xiaoyu Zhang, Xiao Xu, Yama A. Abassi
  • HIGH FREQUENCY MAGNETIC FILMS, METHOD OF MANUFACTURE, AND USES THEREOF
    Publication number: 20200161034
    Abstract: A multilayer film includes a substrate; a first magnetic layer disposed on the substrate and a second magnetic layer disposed on the first magnetic layer. The first magnetic layer includes Fe(50-80)N(10-20)B(1-20)M(0-10), wherein M is Si, Ta, Zr, Ti, Co, or a combination thereof. The second magnetic layer includes Fe(50-90)N(10-50) or Fe(60-90)N(1-10)Ta(5-30). The multilayer magnetic film has, over a frequency range of 50 MHz to 10 GHz, a magnetic permeability of greater than or equal to 1800 over a selected frequency band in the frequency range; a magnetic loss tangent of less than or equal to 0.3 over a selected frequency band in the frequency range; and a cutoff frequency of greater than or equal to 1 GHz, or greater than or equal to 2 GHz.
    Type: Application
    Filed: November 7, 2019
    Publication date: May 21, 2020
    Inventors: Yajie Chen, Xiaoyu Zhang, Li Zhang, Yuanyuan Xing
  • Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereof
    Patent number: 10633376
    Abstract: The present disclosure relates to crystalline forms of JAK1-selective inhibitor, process for preparation and use for prevention and/or treatment of diseases associated with JAK family. The crystalline forms of the present disclosure show favorable properties such as simple preparation process, good stability, low hygroscopicity and good mechanical stability.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 28, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Cunbo Yang, Kai Liu, Xiaoyu Zhang
  • Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
    Patent number: 10626135
    Abstract: The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: April 21, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Po Zou, Kai Liu, Xiaoyu Zhang
  • Crystalline forms of PLX3397 hydrochloride, processes for preparation and use thereof
    Patent number: 10604521
    Abstract: The present disclosure relates to novel crystalline forms of PLX3397 hydrochloride and processes for preparation thereof. The crystalline forms of PLX3397 hydrochloride provided by the present disclosure have higher solubility, larger particle size which is favorable for separation in the subsequent production process, and good stability, especially mechanical stability. These novel crystalline forms of PLX3397 hydrochloride provide a better choice for PLX3397 drug products and are of great value for drug development.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: March 31, 2020
    Assignee: Crystal Pharmaceuticals (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Po Zou, Xiaoyu Zhang
  • Galunisertib crystalline form, preparation method thereof and use thereof
    Patent number: 10604528
    Abstract: The present disclosure relates to a novel crystalline form of Galunisertib, processes for preparation and use thereof. The present disclosure also relates to a pharmaceutical composition comprises the novel crystalline form of Galunisertib and use of the novel crystalline form of Galunisertib and pharmaceutical composition for preparing drugs treating disease. The crystalline form of the present disclosure has good stability, solubility and hygroscopicity, which has significant value for future drug optimization and development.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 31, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Yuhao Chen, Hui Gao, Fei Lu, Xiaoyu Zhang
  • NOVEL CRYSTALLINE FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL] AMINO} ACETIC ACID AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20200095203
    Abstract: The present disclosure relates to novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation and uses thereof. Crystalline form CS1, form CS2 and form CS8 of the present disclosure can be used for preparing drugs treating anemia, which providing new choices for preparing drugs of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid, and having very important value for drug development.
    Type: Application
    Filed: December 13, 2017
    Publication date: March 26, 2020
    Inventors: Minhua Chen, Yanfeng Zhang, Po Zou, Jinqiu Wang, Xiaoyu Zhang
  • METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES
    Publication number: 20200071672
    Abstract: Methods of inducing functional maturation of immature cardiomyocytes derived from induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) by electrically pacing the immature cardiomyocytes according to a pulse profile that induces maturation until the immature cardiomyocytes mature into functionally adult cardiomyocytes.
    Type: Application
    Filed: March 3, 2018
    Publication date: March 5, 2020
    Inventors: Xiaoyu Zhang, Yama A Abassi, Nan Li, Xiaobo Wang
  • Crystalline form E of tafamidis meglumine, process for preparation and use thereof
    Patent number: 10577334
    Abstract: The present disclosure relates to a novel crystalline form E of Tafamidis meglumine, process for preparation and use thereof. When compared with prior crystalline forms, the novel crystalline form of the present disclosure has the advantages of simple process and low hygroscopicity, which provides a new and better choice for the development of Tafamidis meglumine drug product and is of great significance.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: March 3, 2020
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Jiaoyang Li, Xiaoyu Zhang
  • Galunisertib crystalline form, preparation method thereof and use thereof
    Patent number: 10577372
    Abstract: The present disclosure relates to a novel crystalline form of Galunisertib, processes for preparation and use thereof. The present disclosure also relates to a pharmaceutical composition comprises the novel crystalline form of Galunisertib and use of the novel crystalline form of Galunisertib and pharmaceutical composition for preparing drugs treating disease. The crystalline form of the present disclosure has good stability, solubility and hygroscopicity, which has significant value for future drug optimization and development.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Yuhao Chen, Hui Gao, Fei Lu, Xiaoyu Zhang
  • Crystalline form of lenvantinib mesylate and process of preparation thereof
    Patent number: 10562855
    Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: February 18, 2020
    Assignee: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • Crystalline forms of AP26113, and preparation method thereof
    Patent number: 10544129
    Abstract: The present disclosure relates to two novel crystalline forms of AP26113 and processes for preparation thereof. The crystalline form CS1 and crystalline form CS2 of the present disclosure have advantages in solubility and stability, are suitable for development, and provide a better choice for preparation of pharmaceutical compositions containing AP26113, which is of great significance for drug development.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 28, 2020
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Jinqiu Wang, Kai Liu, Xiaoyu Zhang
  • System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
    Patent number: 10539523
    Abstract: Devices, systems and methods for monitoring excitable cells, such as cardiomyocytes, on microelectrode arrays that couple the electro-stimulation of excitable cells to induce or regulate cardiomyocyte beating and the simultaneous measurement of impedance and extracellular recording to assess changes in cardiomyocyte beating, viability, morphology or electrophysical properties in response to a plurality of treatments.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 21, 2020
    Assignee: ACEA Biosciences, Inc.
    Inventors: Xiaobo Wang, Wei Ouyang, Nan Li, Tianxing Wang, Xiaoyu Zhang, Xiao Xu, Yama A. Abassi